← Leaderboards
Gerardo M. Castillo
Pharmain Corporation
$15,494,100
Attributed
$16,626,224
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,626,224 · 12
By mechanism
R44$13,212,427 · 5
R43$3,413,797 · 7
Top collaborators
- Elijah M. Bolotin8 shared
- Sandra Reichstetter2 shared
Most similar at Pharmain Corporation
Same institution · by research overlap
- Elijah M. Bolotin$3,712,057
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsHalf-LifeBloodSuccessPeptidesDoseChronicPreventSmall Business Innovation Research GrantDrug FormulationsAnimalsRattusBaseDrug KineticsNanocarrierTechnologyEfficacy TestingSubcutaneousClinical TrialsCopolymerSafetyPolymersIn VivoBinding (Molecular Function)
Grant awards (26)
Subcutaneous Drug Development for Portal Hypertension Ascites$2,638,464
R44 · FY2025 · DK · contact PI
Subcutaneous Drug Development for Portal Hypertension Ascites$2,145,275
R44 · FY2024 · DK · contact PI
CMC of Peptide Formulation for the Treatment of ARDS$967,740
R44 · FY2023 · HL · contact PI
CMC of Peptide Formulation for the Treatment of ARDS$999,993
R44 · FY2022 · HL · contact PI
Subcutaneous Drug Development for Portal Hypertension Ascites$982,292
R44 · FY2022 · DK · contact PI
Subcutaneous Drug Development for Portal Hypertension Ascites$992,469
R44 · FY2021 · DK · contact PI
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$999,596
R44 · FY2018 · HL · contact PI
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$999,661
R44 · FY2017 · HL · contact PI
Medical countermeasure after radiation exposure$299,815
R43 · FY2015 · AI · contact PI
Subcutaneous Drug Development for Portal Hypertension Ascites$280,313
R43 · FY2015 · DK · contact PI
EGF/Gastrin for Islet Regeneration$749,606
R44 · FY2014 · DK · contact PI
Medical countermeasure after radiation exposure$299,872
R43 · FY2014 · AI · contact PI
Subcutaneous Drug Development for Portal Hypertension Ascites$293,272
R43 · FY2014 · DK · contact PI
Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder$225,000
R43 · FY2014 · AG · contact PI
EGF/Gastrin for Islet Regeneration$794,040
R44 · FY2013 · DK · contact PI
Nanocarrier formulated enzyme for the treatment of S. aureus infection$300,000
R43 · FY2013 · AI · contact PI
Vasoactive intestinal peptide for the treatment of psoriasis$145,203
R43 · FY2013 · AI
Nanocarrier formulated enzyme for the treatment of S. aureus infection$300,000
R43 · FY2012 · AI · contact PI
Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases$299,973
R43 · FY2012 · AI · contact PI
Vasoactive intestinal peptide for the treatment of psoriasis$226,765
R43 · FY2012 · AI
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR$432,304
R44 · FY2011 · AA · contact PI
Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases$299,976
R43 · FY2011 · AI · contact PI
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR$350,624
R44 · FY2010 · AA · contact PI
EGF/Gastrin for Islet Cell Regeneration$229,824
R43 · FY2010 · DK · contact PI
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR$160,363
R44 · FY2010 · AA · contact PI
EGF/Gastrin for islet cell regeneration$213,784
R43 · FY2009 · DK · contact PI